After careers in Pharma and MedTech, the co-founders were eager to drive innovation and help people rather than get slowed down by corporate structures. They joined Evoleen, an incubator partnering with health industry players, co-creating new ventures to accelerate innovation. After prototyping several digital health initiatives, they started the SIVA project in coordination with the global pharmaceutical company Bayer, which was developing a novel drug targeting refractory chronic cough. From the successful initial feasibility project findings, it became clear that the team was holding the keys to addressing many important unmet needs in the cough space. They co-founded SIVA Health and have been driving the vision of providing better lives for respiratory patients ever since.
 
After Bayer discontinued its refractory chronic cough drug development project, SIVA Health became fully independent and owns all generated IPs. Today, the team works with several leading global pharmaceutical companies to support their efforts to develop better treatment options for respiratory patients.
 

2024-07 SIVA Health AG has received certification according to the European Medical Device Regulation (EU) 2017/745 for its continuous cough monitoring system. It is the first fully automated AI-based continuous ambulatory cough monitoring system that has been approved as a medical device.

2023-11 SIVA being used as the first AI-based continuous ambulatory cough measurement system in a global drug development study, providing cough profiles over several weeks

2023-07 SIVA Health AG becoming a fully independent company, owning all the IP generated.

2023-03 Start of clinical validation study in the U.S. at the Bellingham Asthma, Allergy & Immunology Clinic. Identifier: NCT05689307

2022-10 Clinical results of the SIVA validation study published in ERJ Open Research. First publication on AI-based continuous ambulatory cough monitoring over several weeks with a large number of patients.

2022-04 Certification according to EN ISO 13485:2016

2021-04 Start of clinical validation study at the University Hospital Zurich. First study on continuous cough monitoring over several weeks with a large number of patients

2020-04 SIVA Health Founded. Initiation of AI-based continuous ambulatory cough monitoring project in close collaboration with Bayer Pharmaceuticals